Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 716

1.

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.

Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, Paris M, Mease PJ.

Arthritis Res Ther. 2019 May 10;21(1):118. doi: 10.1186/s13075-019-1901-3.

2.

Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC.

Patrick MT, Stuart PE, Raja K, Chi S, He Z, Voorhees JJ, Tejasvi T, Gudjonsson JE, Kahlenberg JM, Chandran V, Rahman P, Gladman DD, Nair RP, Elder JT, Tsoi LC.

Front Genet. 2019 Apr 11;10:304. doi: 10.3389/fgene.2019.00304. eCollection 2019.

3.

All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013).

Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M.

Ann Rheum Dis. 2019 Jun;78(6):802-806. doi: 10.1136/annrheumdis-2018-214802. Epub 2019 Apr 16.

PMID:
30992296
4.

Construction of a frailty index as a novel health measure in systemic lupus erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

J Rheumatol. 2019 Apr 15. pii: jrheum.181338. doi: 10.3899/jrheum.181338. [Epub ahead of print]

PMID:
30988130
5.

Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.

Chandran V, Abji F, Perruccio AV, Gandhi R, Li S, Cook RJ, Gladman DD.

Ann Rheum Dis. 2019 Jun;78(6):796-801. doi: 10.1136/annrheumdis-2018-214737. Epub 2019 Mar 25.

PMID:
30910989
6.

The development of a modified Psoriatic Arthritis Disease Activity Score (mPASDAS) using SF-12 as a measure of quality of life.

Perruccio AV, Got M, Li S, Ye Y, Gladman DD, Chandran V.

Arthritis Care Res (Hoboken). 2019 Mar 15. doi: 10.1002/acr.23876. [Epub ahead of print]

PMID:
30875460
7.

Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L.

J Rheumatol. 2019 Mar 1. pii: jrheum.180971. doi: 10.3899/jrheum.180971. [Epub ahead of print]

8.

Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis.

Pollock RA, Zaman L, Chandran V, Gladman DD.

PLoS One. 2019 Feb 19;14(2):e0212043. doi: 10.1371/journal.pone.0212043. eCollection 2019.

9.

Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin P, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Steinsson K, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG.

Arthritis Rheumatol. 2019 Feb 16. doi: 10.1002/art.40859. [Epub ahead of print]

PMID:
30771242
10.

Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 Psoriatic Arthritis workshop report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Feb 15. pii: jrheum.181089. doi: 10.3899/jrheum.181089. [Epub ahead of print]

PMID:
30770518
11.

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón G, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet E.

Rheumatology (Oxford). 2019 Feb 8. doi: 10.1093/rheumatology/kez014. [Epub ahead of print]

PMID:
30753683
12.

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase 3 Trial.

Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB.

Arthritis Rheumatol. 2019 Feb 12. doi: 10.1002/art.40851. [Epub ahead of print]

PMID:
30747501
13.

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019.

14.

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. eCollection 2019.

15.

Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story.

Urowitz MB, Su J, Gladman DD.

J Rheumatol. 2019 Feb 1. pii: jrheum.180986. doi: 10.3899/jrheum.180986. [Epub ahead of print]

PMID:
30709950
16.

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.

Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, Rathmann S, Shrom D, Marzo-Ortega H.

Arthritis Res Ther. 2019 Jan 29;21(1):38. doi: 10.1186/s13075-019-1831-0.

17.

Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.

Wirestam L, Enocsson H, Skogh T, Padyukov L, Jönsen A, Urowitz MB, Gladman DD, Romero-Diaz J, Bae SC, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bernatsky S, Gordon C, Hanly JG, Wallace D, Isenberg DA, Rahman A, Merrill J, Ginzler E, Alarcón GS, Chatham WW, Petri M, Khamashta M, Aranow C, Mackay M, Dooley MA, Manzi S, Ramsey-Goldman R, Nived O, Steinsson K, Zoma A, Ruiz-Irastorza G, Lim S, Kalunian K, Inanc M, van Vollenhoven R, Ramos-Casals M, Kamen DL, Jacobsen S, Peschken C, Askanase A, Stoll T, Bruce IN, Wetterö J, Sjöwall C.

J Rheumatol. 2019 May;46(5):492-500. doi: 10.3899/jrheum.180713. Epub 2019 Jan 15.

18.

Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis.

Polachek A, Cook R, Chandran V, Gladman DD, Eder L.

Arthritis Res Ther. 2019 Jan 14;21(1):20. doi: 10.1186/s13075-019-1814-1.

19.

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort.

Mendel A, Bernatsky SB, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Wallace DJ, Merrill JT, Buyon JP, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin PR, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN, Costedoat-Chalumeau N, Vinet É.

Ann Rheum Dis. 2018 Dec 20. pii: annrheumdis-2018-214434. doi: 10.1136/annrheumdis-2018-214434. [Epub ahead of print] No abstract available.

20.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2018 Dec 15. pii: jrheum.180478. doi: 10.3899/jrheum.180478. [Epub ahead of print]

PMID:
30554156
21.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Callis Duffin K, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2018 Dec 15. pii: jrheum.181077. doi: 10.3899/jrheum.181077. [Epub ahead of print]

PMID:
30554154
22.

Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls.

Polachek A, Polachek Shlomi I, Spitzer K, Pereira D, Ye JY, Chandran V, Laskin CA, Gladman DD.

Clin Rheumatol. 2019 Mar;38(3):895-902. doi: 10.1007/s10067-018-4385-7. Epub 2018 Dec 7.

PMID:
30535992
23.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

24.

Disease course patterns in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Lupus. 2019 Jan;28(1):114-122. doi: 10.1177/0961203318817132. Epub 2018 Dec 8.

PMID:
30526328
25.

What Is Axial Psoriatic Arthritis?

Feld J, Chandran V, Gladman DD.

J Rheumatol. 2018 Dec;45(12):1611-1613. doi: 10.3899/jrheum.180802. No abstract available.

PMID:
30504477
26.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):2-29. doi: 10.1002/acr.23789. Epub 2018 Nov 30.

PMID:
30499259
27.

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J.

Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.

PMID:
30499246
28.

Correction to: Psoriasis in systemic lupus erythematosus: a single-center experience.

Tselios K, Yap KS, Pakchotanon R, Polachek A, Su J, Urowitz MB, Gladman DD.

Clin Rheumatol. 2019 Jan;38(1):269. doi: 10.1007/s10067-018-4363-0.

PMID:
30430267
29.

How can we define low disease activity in systemic lupus erythematosus?

Tselios K, Gladman DD, Urowitz MB.

Semin Arthritis Rheum. 2018 Oct 16. pii: S0049-0172(18)30485-2. doi: 10.1016/j.semarthrit.2018.10.013. [Epub ahead of print]

PMID:
30415943
30.

Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set.

Elmamoun M, Leung YY, O'Sullivan D, Steinkoenig I, Chandran V, Gladman DD, FitzGerald OM, Orbai AM, Eder L.

J Rheumatol. 2019 Mar;46(3):266-273. doi: 10.3899/jrheum.180195. Epub 2018 Nov 1.

PMID:
30385708
31.

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Rheumatol. 2019 Feb;71(2):281-289. doi: 10.1002/art.40764. Epub 2019 Jan 18.

32.

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.

Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD.

Lancet. 2018 Dec 1;392(10162):2367-2377. doi: 10.1016/S0140-6736(18)32483-8. Epub 2018 Oct 22.

33.

Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?

Tselios K, Deeb M, Gladman DD, Harvey P, Akhtari S, Mak S, Butany J, Urowitz MB.

J Rheumatol. 2019 Apr;46(4):391-396. doi: 10.3899/jrheum.180124. Epub 2018 Oct 15.

PMID:
30323009
34.

Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients.

Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, Chandran V, Das S, Callis-Duffin K, Ellinghaus E, Enerbäck C, Esko T, Franke A, Kang HM, Krueger GG, Lim HW, Rahman P, Rosen CF, Weidinger S, Weichenthal M, Wen X, Voorhees JJ, Abecasis GR, Gladman DD, Nair RP, Elder JT, Tsoi LC.

Nat Commun. 2018 Oct 9;9(1):4178. doi: 10.1038/s41467-018-06672-6.

35.

Classification and Outcome Measures for Psoriatic Arthritis.

Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD.

Front Med (Lausanne). 2018 Sep 6;5:246. doi: 10.3389/fmed.2018.00246. eCollection 2018. Review.

36.

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus.

Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, Bourre-Tessier J, Clarke A, Baril-Dionne A, Dutz J, Ensworth S, Fifi-Mah A, Fortin PR, Gladman DD, Haaland D, Hanly JG, Hiraki LT, Hussein S, Legault K, Levy D, Lim L, Matsos M, McDonald EG, Medina-Rosas J, Pardo Pardi J, Peschken C, Pineau C, Pope J, Rader T, Reynolds J, Silverman E, Tselios K, Suitner M, Urowitz M, Touma Z, Vinet E, Santesso N.

J Rheumatol. 2018 Oct;45(10):1426-1439. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1.

37.

Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: A population-based study.

Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R, Paterson JM, Cheng SY, Jabbari S, Campbell W, Bernatsky S, Gladman DD, Tu K.

Arthritis Care Res (Hoboken). 2018 Sep 1. doi: 10.1002/acr.23743. [Epub ahead of print]

PMID:
30171803
38.

Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis.

Yap KS, Ye JY, Li S, Gladman DD, Chandran V.

Ann Rheum Dis. 2018 Nov;77(11):1573-1577. doi: 10.1136/annrheumdis-2018-213334. Epub 2018 Aug 4.

PMID:
30077991
39.

Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?

Tselios K, Gladman DD, Harvey P, Akhtari S, Su J, Urowitz MB.

J Rheumatol. 2019 Jan;46(1):64-69. doi: 10.3899/jrheum.171436. Epub 2018 Aug 1.

PMID:
30068764
40.

Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.

Keeling SO, Bissonauth A, Bernatsky S, Vandermeer B, Fortin PR, Gladman DD, Peschken C, Urowitz MB.

J Rheumatol. 2018 Oct;45(10):1440-1447. doi: 10.3899/jrheum.171307. Epub 2018 Aug 1.

41.

The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis.

Zhou W, Chandran V, Cook R, Gladman DD, Eder L.

Semin Arthritis Rheum. 2019 Feb;48(4):638-643. doi: 10.1016/j.semarthrit.2018.06.001. Epub 2018 Jun 19.

PMID:
30057322
42.

Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720. [Epub ahead of print]

PMID:
30055090
43.

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ.

Arthritis Care Res (Hoboken). 2018 Jul 25. doi: 10.1002/acr.23712. [Epub ahead of print]

PMID:
30044551
44.

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.

Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ.

RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.

45.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Oct 1;57(10):1777-1788. doi: 10.1093/rheumatology/key161.

46.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.

PMID:
29928910
47.

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kuijk AWR, Catanoso MG, Caso F, Contu P, Ujfalussy I, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group.

J Rheumatol. 2018 Aug;45(9):1256-1262. doi: 10.3899/jrheum.171183. Epub 2018 Jun 15.

PMID:
29907666
48.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.

PMID:
29858357
49.

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

Gladman DD, Coates LC, Jadon DR, Tillett W, Mease PJ, Vis M.

J Rheumatol Suppl. 2018 Jun;94:26-29. doi: 10.3899/jrheum.180132.

PMID:
29858349
50.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348

Supplemental Content

Loading ...
Support Center